|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 860 WINTER STREET |
Address2 |
|
City | WALTHAM |
State | MA |
Zip Code | 02451 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 23975-12
|
||||||||
|
6. House ID# 319670000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Lois Dehls Cornell, Executive Vice President |
Date | 10/18/2023 3:36:58 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Childcare
Issues related to childcare - no specific bill
COVID-19
General Advocacy on COVID-19 relief, response, and pandemic preparedness, including issues related to:
Support for resident physicians and medical students
Student loan forgiveness/debt relief
Demographic data collection
Telemedicine/Telehealth
Vaccines
Testing, contact tracing, and mitigation
Health disparities and protecting vulnerable populations
Mental and behavioral health
Expanding internet connectivity/broadband
Incentives and federal funding to expand Medicaid and CHIP eligibility
Allowing states to extend Medicaid and CHIP eligibility to women for 12 months postpartum.
COVID-19 PHE Wind Down - no specific bill
Gun Safety
Issues related to gun safety - no specific bill
Gun Violence Prevention and Community Safety Act
Health Care
Issues related to health care/universal access to quality, equitable, affordable coverage - no specific bill
Issues related to mental and behavioral health care - no specific bill
Health Care Workforce
Issues related to health care workforce shortages - no specific bill
Issues related to the affordability of medical education and federal loan programs - no specific bill
Issues related to scope of practice - no specific bill
Issues related to the Department of Veterans Affairs Federal Supremacy Project - no specific bill
Immigration
Issues related to Immigration - no specific bill
Conrad 30 Waiver Program - no specific bill
Protecting Immigrant Families (PIF) Campaign
Infrastructure
Issues related to broadband access - no specific bill
Issues related to the Build Back Better framework - no specific bill
Interoperability/ONC
Issues related to interoperability and information blocking - no specific bill
Maternal Health
Issues related to maternal health - no specific bill
Medical Education
Issues related to the affordability of medical education - no specific bill
Medicare/Medicaid
Cigna Modifier 25
H.R. 2474 the Strengthening Medicare for Patients and Providers Act
H.R.2173 the Improving Care and Access to Nurses Act
Issues related to Medicare physician payment - no specific bill
H.R. 2474 Strengthening Medicare for Patients and Providers Act
Issues related to Medicare/Medicaid - no specific bill
Issues related to prior authorization and administrative simplification - no specific bill
Issues related to Medicare Advantage risk adjustment - no specific bill
Nutrition
Issues related to nutrition and food security - no specific bill
Issues related to SNAP funding - - no specific bill
Opioids/ Substance Use Disorder
LABEL Opioids Act of 2023
Issues related to opioids and substance use disorder - no specific bill
MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment
S.1785, STOP Fentanyl Overdoses Act of 2023
Prescription Drug Pricing
Issues related to prescription drug pricing - no specific bill
S. 470/HR 977, The Patient Access to Higher Quality Health Care Act
Publications
Open access to information based on publicly funded research - no specific bill
Request for Information for NIH Plan to Enhance Public Access to the Results of NIH-Supported Research
Issues related to scholarly and scientific publishing and public access - no specific bill
H.R. 9378, Sunshine Act of 2023
Racial Justice/Health Equity
Issues related to racial justice/health care equity - no specific bill
Issues related to equitable policies around blood, tissue donations - no specific bill
Surprise Billing
Issues related to surprise billing - no specific bill
Issues related to the implementation of the No Surprises Act
Telehealth
Issues related to telehealth - no specific bill
Issues related to telebehavioral health access - no specific bill
Issues related to physician licensing - no specific bill
Issues related to telehealth PHE flexibilities/waivers - no specific bill
Tobacco
Issues related to prohibiting sale of menthol cigarettes and flavored cigars - no specific bill
Issues related to increasing awareness about lung cancer screening on cigarette packages - no specific bill
Vaccines
Issues related to vaccines - no specific bill
Regulatory
Medicare Fee Schedule
FDA's proposed rule to eliminate menthol cigarettes
Issues related to Medicare physician payment
Issues related to implementation of the No Surprises Act
Issues related to telehealth
Issues related to health equity
File Code CMS-1784-P. Medicare and Medicaid Programs; CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Advantage; Medicare and Medicaid Provider and Supplier Enrollment Policies; and Basic Health Program
Support Section 552 of the House CJS mark, which would block certain funding for implementation of the August 2022 Office of Science and Technology Policy (OSTP) public access memorandum.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Drug Enforcement Administration (DEA), Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Casey |
Rojas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Childcare
Issues related to childcare - no specific bill
COVID-19
General Advocacy on COVID-19 relief, response, and pandemic preparedness, including issues related to:
Support for resident physicians and medical students
Student loan forgiveness/debt relief
Demographic data collection
Telemedicine/Telehealth
Vaccines
Testing, contact tracing, and mitigation
Health disparities and protecting vulnerable populations
Mental and behavioral health
Expanding internet connectivity/broadband
Incentives and federal funding to expand Medicaid and CHIP eligibility
Allowing states to extend Medicaid and CHIP eligibility to women for 12 months postpartum.
COVID-19 PHE Wind Down - no specific bill
Gun Safety
Issues related to gun safety - no specific bill
Gun Violence Prevention and Community Safety Act
Health Care
Issues related to health care/universal access to quality, equitable, affordable coverage - no specific bill
Issues related to mental and behavioral health care - no specific bill
Health Care Workforce
Issues related to health care workforce shortages - no specific bill
Issues related to the affordability of medical education and federal loan programs - no specific bill
Issues related to scope of practice - no specific bill
Issues related to the Department of Veterans Affairs Federal Supremacy Project - no specific bill
Immigration
Issues related to Immigration - no specific bill
Conrad 30 Waiver Program - no specific bill
Protecting Immigrant Families (PIF) Campaign
Infrastructure
Issues related to broadband access - no specific bill
Issues related to the Build Back Better framework - no specific bill
Interoperability/ONC
Issues related to interoperability and information blocking - no specific bill
Maternal Health
Issues related to maternal health - no specific bill
Medical Education
Issues related to the affordability of medical education - no specific bill
Medicare/Medicaid
Cigna Modifier 25
H.R. 2474 the Strengthening Medicare for Patients and Providers Act
H.R.2173 the Improving Care and Access to Nurses Act
Issues related to Medicare physician payment - no specific bill
H.R. 2474 Strengthening Medicare for Patients and Providers Act
Issues related to Medicare/Medicaid - no specific bill
Issues related to prior authorization and administrative simplification - no specific bill
Issues related to Medicare Advantage risk adjustment - no specific bill
Nutrition
Issues related to nutrition and food security - no specific bill
Issues related to SNAP funding - - no specific bill
Opioids/ Substance Use Disorder
LABEL Opioids Act of 2023
Issues related to opioids and substance use disorder - no specific bill
MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment
S.1785, STOP Fentanyl Overdoses Act of 2023
Prescription Drug Pricing
Issues related to prescription drug pricing - no specific bill
S. 470/HR 977, The Patient Access to Higher Quality Health Care Act
Publications
Open access to information based on publicly funded research - no specific bill
Request for Information for NIH Plan to Enhance Public Access to the Results of NIH-Supported Research
Issues related to scholarly and scientific publishing and public access - no specific bill
H.R. 9378, Sunshine Act of 2023
Racial Justice/Health Equity
Issues related to racial justice/health care equity - no specific bill
Issues related to equitable policies around blood, tissue donations - no specific bill
Surprise Billing
Issues related to surprise billing - no specific bill
Issues related to the implementation of the No Surprises Act
Telehealth
Issues related to telehealth - no specific bill
Issues related to telebehavioral health access - no specific bill
Issues related to physician licensing - no specific bill
Issues related to telehealth PHE flexibilities/waivers - no specific bill
Tobacco
Issues related to prohibiting sale of menthol cigarettes and flavored cigars - no specific bill
Issues related to increasing awareness about lung cancer screening on cigarette packages - no specific bill
Vaccines
Issues related to vaccines - no specific bill
Regulatory
Medicare Fee Schedule
FDA's proposed rule to eliminate menthol cigarettes
Issues related to Medicare physician payment
Issues related to implementation of the No Surprises Act
Issues related to telehealth
Issues related to health equity
File Code CMS-1784-P. Medicare and Medicaid Programs; CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Advantage; Medicare and Medicaid Provider and Supplier Enrollment Policies; and Basic Health Program
Support Section 552 of the House CJS mark, which would block certain funding for implementation of the August 2022 Office of Science and Technology Policy (OSTP) public access memorandum.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Drug Enforcement Administration (DEA), Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Casey |
Rojas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Publications
Open access to information based on publicly funded research - no specific bill
Request for Information for NIH Plan to Enhance Public Access to the Results of NIH-Supported Research
Issues related to scholarly and scientific publishing and public access - no specific bill
H.R. 9378, Sunshine Act of 2023
Support Section 552 of the House CJS mark, which would block certain funding for implementation of the August 2022 Office of Science and Technology Policy (OSTP) public access memorandum.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Casey |
Rojas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
Immigration
Issues related to Immigration - no specific bill
Conrad 30 Waiver Program - no specific bill
Protecting Immigrant Families (PIF) Campaign
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Casey |
Rojas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
Medical Education
Issues related to the affordability of medical education - no specific bill
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health Resources & Services Administration (HRSA), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Casey |
Rojas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Prescription Drug Pricing
Issues related to prescription drug pricing - no specific bill
S. 470/HR 977, The Patient Access to Higher Quality Health Care Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Casey |
Rojas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Opioids/ Substance Use Disorder
LABEL Opioids Act of 2023
Issues related to opioids and substance use disorder - no specific bill
MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment
S.1785, STOP Fentanyl Overdoses Act of 2023
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Casey |
Rojas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIR
16. Specific lobbying issues
Gun Safety
Issues related to gun safety - no specific bill
Gun Violence Prevention and Community Safety Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Casey |
Rojas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Surprise Billing
Issues related to surprise billing - no specific bill
Issues related to the implementation of the No Surprises Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Casey |
Rojas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Tobacco
Issues related to prohibiting sale of menthol cigarettes and flavored cigars - no specific bill
Issues related to increasing awareness about lung cancer screening on cigarette packages - no specific bill
FDA's proposed rule to eliminate menthol cigarettes
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Casey |
Rojas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |